News for Amgen
Dec 7 · 4:07:00 PM · Source: Reuters
Amgen announced that its Board of Directors has authorized repurchases of up to an additional $5 billion in Amgen common stock.
Amgen currently has approximately $1.2 billion remaining under its previous stock repurchase authorization.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto
Nov 5 · 3:29:00 PM · Source: Reuters
Amgen announced that the Phase 3 PRIME 203 trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto
Nov 3 · 1:30:00 PM · Source: Reuters
Amgen, Inc. and AmerisourceBergen Corp. were sued on Friday by 14 U.S. states and the District of Columbia over an alleged kickback scheme designed to boost sales of Amgen's anemia drug, Aranesp.
New York Attorney General Andrew Cuomo announced the lawsuit, which was filed in federal court in Boston. It joins a related whistleblower lawsuit filed in the same court in 2006 and is one of many lawsuits accusing drugmakers of illegally marketing their products.
· Related: AmerisourceBergen
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto
Oct 28 · 12:28:00 PM · Source: Reuters
A British charitable trust filed a patent infringement suit against Amgen and Wyeth on Wednesday over their blockbuster Enbrel drug, one of the world's best-selling treatments for rheumatoid arthritis.
The Mathilda and Terence Kennedy Institute of Rheumatology Trust asked a federal court in Delaware to grant royalty payments and damages from Wyeth and Amgen for infringing a patent for treating arthritis.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto
Oct 22 · 10:47:00 AM · Source: Press Release
Amgen reported Q3 earnings of $1.49 on net income of $1.5 billion versus $1.23 on net income of $1.3 billion in the year ago period. Total revenue decreased 2% during the quarter to $3.8 billion.
"Our third quarter results reflect the continued stability of our core
businesses in the face of increased competition," said Kevin Sharer, chairman
& chief executive officer. "We are pleased by the results of clinical studies
for denosumab and Vectibix that we recently presented at a scientific meeting,
and look forward to making these innovative medicines available to patients in
their respective indications."
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto
Oct 15 · 11:17:00 AM · Source: Easy Bourse
Amgen’s new osteoporosis drug, Denosumab, which is scheduled for FDA approval on October 19, may now be delayed.
Denosumab is viewed by some as the most significant biotech launch in years. Analysts are now expecting a possible 3-month delay in approval because the FDA may want more time to study the drug’s safety record.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto
Advertisement